natgillin/translations-raw huggingface dataset:
Approximately 60% of cinacalcet-treated patients achieved a ≥ 30% reduction in iPTH levels, and this effect was consistent across the spectrum of baseline iPTH levels.
Oko 60 % bolesnika liječenih sinakalcetom postiglo je sniženje vrijednosti iPTH za ≥ 30 % i taj učinak bio je stalan, bez obzira na početnu vrijednost iPTH-a.
Approximately 60% of cinacalcet-treated patients achieved a  30% reduction in iPTH levels, and this effect was consistent across the spectrum of baseline iPTH levels.
Oko 60 % bolesnika liječenih sinakalcetom postiglo je sniženje vrijednosti iPTH za ≥ 30 % i taj učinak bio je stalan, bez obzira na početnu vrijednost iPTH-a.
Approximately 60-70% of the dose was recovered in the urine as active substance.
Oko 60 – 70 % primijenjene doze nađe se u urinu u obliku djelatne tvari.
Approximately 65% of an i.v. dose is renally excreted within the first 24 hours.
Oko 65 % intravenske doze bubrežno se izlučuje unutar prva 24 sata.
Approximately 68% of patients in Group A and 63% of patients in Group B had been treated with dabigatran 110 mg twice daily.
Približno 68% bolesnika u skupini A te 63% bolesnika u skupini B liječeni su dabigatranom 110 mg dvaput dnevno.
Approximately 6–16% of the administered dose was excreted in the urine as unchanged drug.
Otprilike 6-16% primijenjene doze bilo je izlučeno u mokraći kao nepromijenjeni lijek.
Approximately 7% of an oral dose is excreted as unchanged 6– mercaptopurine within 12 hours after administration.
Približno 7% oralne doze izlučuje se kao nepromijenjeni 6-merkaptopurin unutar 12 sati nakon primjene.
Approximately 7-8% of individuals of Caucasian descent, 3-6% of Black African descent, 2-3% of Arab descent and 1-2% of Asian descent generally lack the capacity to metabolize CYP2D6 substrates and are classified as Poor Metabolizer (PMs).
Nedostatak sposobnosti za metabolizaciju supstrata CYP2D6 uglavnom ima približno 7-8% bijelaca, 3-6% crnaca, 2-3% osoba arapskog podrijetla i 1-2% azijata pa su klasificirani kao slabi metabolizatori.
Approximately 70 % of patients treated with Rebif can expect to experience the typical interferon flu-like syndrome within the first six months after starting treatment.
Tijekom prvih šest mjeseci liječenja Rebifom otprilike 70% bolesnika može očekivati pojavu tipičnog sindroma sličnog gripi specifičnih za interferon.
Approximately 70 patients from study EGF114299 who have been randomised to the lapatinib + AI arm with an exposure of approximately 6 months.
Oko 70 bolesnika iz ispitivanja EGF114299 koji su randomizirani na lapatinib u kombinaciji s inhibitorom aromataze uz izloženost u trajanju od oko 6 mjeseci.
Approximately 70–80% of pirfenidone is metabolised via CYP1A2 with minor contributions from other CYP isoenzymes including CYP2C9, 2C19, 2D6, and 2E1.
Približno 70–80% pirfenidona metabolizira se uz pomoć CYP1A2, uz manji doprinos drugih CYP izoenzima, uključujući CYP2C9, 2C19, 2D6 i 2E1.
Approximately 70–80% of pirfenidone is metabolised via CYP1A2 with minor contributions from other CYP isoenzymes including CYP2C9, 2C19, 2D6, and 2E1.
Približno se 70-80% pirfenidona metabolizira uz pomoć CYP1A2, uz manji doprinos drugih izoenzima CYP, uključujući CYP2C9, 2C19, 2D6 i 2E1.
Approximately 75 % of the administered dose is eliminated via faeces and the remainder via urine.
Oko 75% unesene doze eliminira se putem izmeta dok se ostatak izlučuje mokraćom.
Approximately 75 % of the administered dose is eliminated via faeces and the remainder via urine.
Otprilike 75% primijenjene doze izlučuje se izmetom, a ostatak u mokraći.
Approximately 75 % of the administered dose is eliminated via faeces and the remainder via urine.
Približno 75% doze izlučuje se izmetom, a ostatak mokraćom.
Approximately 75% of the administered [14C] nateglinide is recovered in the urine within six hours post-dose.
Otprilike 75% primijenjenog [14C] nateglinida izluči se u mokraću u roku od šest sati nakon uzimanja doze.
Approximately 75% of the administered dose is eliminated via faeces and the remainder via urine.
Otprilike 75% primijenjene doze izlučuje se izmetom, a ostatak mokraćom.
Approximately 75% of the administered dose is eliminated via faeces and the remainder via urine.
Približno 75 % primijenjene doze izlučuje se izmetom, a ostatak mokraćom.
Approximately 78% of the subjects on 20 mg esomeprazole reported first resolution of heartburn within the first week of treatment compared to 52 – 58% for placebo.
Približno 78% ispitanika liječenih s 20 mg esomeprazola prijavilo je prvo povlačenje žgaravice unutar prvoga tjedna liječenja u usporedbi s 52-58% bolesnika koji su primali placebo.
Approximately 8% of patients had a severe ADR (common toxicity criteria, (CTC) grade 3 or 4).
Približno 8% bolesnika imalo je teške nuspojave (stupnja 3 ili 4 prema općim kriterijima toksičnosti (common toxicity criteria, CTC)).
Approximately 80% of patients developed neutralizing antibodies capable of inhibiting the elosulfase alfa from binding to the cation- independent mannose-6-phosphate receptor.
Otprilike 80% bolesnika razvilo je neutralizirajuća antitijela sposobna inhibirati elosulfazu alfa od vezanja na kation neovisni manoza-6-fosfat receptor.
Approximately 85% of patients receiving LEMTRADA tested positive for anti-alemtuzumab antibodies during the study, with 92% of these patients testing positive also for antibodies that inhibited LEMTRADA binding in vitro.
Tijekom ispitivanja je približno 85% bolesnika koji su primali lijek LEMTRADA bilo pozitivno na protutijela na alemtuzumab, a 92% tih bolesnika bilo je također pozitivno na protutijela koja su sprečavala vezivanje lijeka LEMTRADA in vitro.
Approximately 90 % of 14C-labelled dose is excreted through the kidneys while less than 2% is found in the faeces.
Oko 90% doze označene radioaktivnim ugljikom 14C izlučuje se putem bubrega, dok se manje od 2% nalazi u fecesu.
Approximately 90% of spinosad is comprised of spinosyns A and D. Of that 90%, the ratio of spinosyn A to A+D is 0.85 when calculated as spinosyn A/spinosyn A+D. The consistency of this figure in pharmacokinetic and other studies indicates comparability in the absorption, metabolism and elimination of the two major spinosyns.
Oko 90% spinosada sadrži spinosin A i D. Od tih 90%, odnos spinosina A prema A+D je 0,85 kad se računa spinosin A/spinosin A+D. Postojanost ovih iznosa u farmakokinetičkim i drugim ispitivanjima pokazuje usporedivost apsorpcije, metabolizma i eliminacije dva glavna spinosina.
Approximately 97% of meloxicam is bound to plasma proteins.
Približno 97 % meloksikama veže se na proteine u plazmi.
Approximately 98 % of meloxicam is bound to plasma proteins.
Približno 98% meloksikama vezano je za bjelančevine plazme.
Approximately 98% of meloxicam is bound to plasma proteins.
Približno 98% meloksikama veže se na proteine plazme.
Approximately 9–17 % of patients treated with Taltz at the recommended dosing regimen developed anti-drug antibodies, the majority of which were low titres and not associated with reduced clinical response up to 60 weeks of treatment.
Približno 9 – 17% bolesnika liječenih lijekom Taltz prema preporučenom režimu doziranja razvilo je protutijela na lijek, koja su se u većini slučajeva javljala u niskim titrima te nisu bila povezana sa smanjenim kliničkim odgovorom tijekom razdoblja do 60 tjedana liječenja.
Approximately half of all patients had 3 or more organs involved in their disease and most patients had the lung (74 %), and/or lymph nodes (54 %) as a metastatic location for disease at baseline.
Približno je polovica svih bolesnika imala 3 ili više organa zahvaćenih bolešću, te su kod većine bolesnika pluća (74%) i/ili limfni čvorovi (54%) bili sijela metastaza na početku ispitivanja.
Approximately half of the patients had at least 3 years of prior exposure to Viramune immediate-release prior to entering study 1100.1526.
Oko polovine bolesnika je imalo najmanje 3 godine prethodnog izlaganja Viramuneu s trenutnim oslobađanjem prije ulaska u ispitivanje 1100.1526.
Approximately half of the patients who developed an ANC < 1 x 109/ l did so within 8 weeks after starting therapy.
U približno polovice bolesnika koji su imali apsolutni broj neutrofila < 1 x 109/ l smanjenje broja nastupilo je u roku od 8 tjedana od početka terapije.
Approximately half the patients in each treatment group had hormone receptor-positive disease (defined as estrogen receptor (ER) positive and/or progesterone receptor (PgR) positive) and approximately half of the patients in each treatment group had received prior adjuvant or neoadjuvant therapy.
Približno je polovica bolesnika u svakoj terapijskoj skupini imala bolest pozitivnu na hormonske receptore (definirano kao bolest pozitivna na estrogenske receptore (ER-pozitivna) i/ili na progesteronske receptore (PgR-pozitivna)) i približno je polovica bolesnika u svakoj terapijskoj skupini prethodno primala adjuvantno ili neoadjuvantno liječenje.
Approximately half the radioactivity administered orally as [14C]­netupitant was recovered from urine and faeces within 120 h of dosing.
Približno pola radioaktivnosti primijenjene peroralno kao [14C]­netupitant otkriveno je u mokraći i stolici unutar 120 h od primjene doze.
Approximately one third of patients can be expected to experience adverse reactions following treatment with tenofovir disoproxil fumarate in combination with other antiretroviral agents.
Može se očekivati da će približno jedna trećina pacijenata razviti nuspojave nakon liječenja tenofovirdizoproksilfumaratom u kombinaciji s drugim antiretrovirusnim lijekovima.
Approximately one-third of patients had failed prior TNF antagonist therapy.
Približno jedna trećina bolesnika nije odgovorila na prethodno liječenje antagonistom TNF.
Approximately one-third of the patients enrolled (76 [33.8%] in the Ilaris group and 84 [36.7%] in the triamcinolone acetonide group) had documented inability (intolerance, contraindication or lack of response) to use both NSAIDs and colchicine.
Otprilike jedna trećina uključenih bolesnika (76 [33,8%] u skupini koja je primala Ilaris i 84 [36,7%] u skupini koja je primala triamcinolon acetonid) imala je dokumentiranu nemogućnost (zbog intolerancije, kontraindikacija ili nedostatka odgovora) korištenja NSAIL-a i kolhicina.
Approximately two to three fold increases in clobazam and five fold increases in norclobazam plasma levels respectively have been reported with co-administration of stiripentol in children with Dravet’s syndrome.
Uz dodatnu primjenu stiripentola u djece s Dravetovim sindromom zabilježeno je približno dvostruko do trostrukog povećanje razine klobazama u plazmi, odnosno petorostruko povećanje razine norklobazama u plazmi.
Apr  Aug  Dec
Travanj  Kolovoz  Prosinac
Apremilast
terapija N=162
Apremilast 30 mg BID
Apremilast
Apremilast administered at doses of up to 50 mg BID did not prolong the QT interval in healthy subjects.
Apremilast primijenjen u dozama do 50 mg BID nije produljio QT interval u zdravih ispitanika.
Apremilast can be co-administered with a potent CYP3A4 inhibitor such as ketoconazole.
Apremilast se može primjenjivati istodobno s jakim inhibitorom enzima CYP3A4 kao što je ketokonazol.
Apremilast has no influence on the ability to drive and use machines.
Apremilast ne utječe na sposobnost upravljanja vozilima i rada sa strojevima.
Apremilast is contraindicated during pregnancy.
Apremilast je kontraindiciran tijekom trudnoće.
Apremilast was not clastogenic in an in vivo mouse micronucleus assay at doses up to 2000 mg/kg/day.
Apremilast nije bio klastogen u in vivo testu mišjih mikronukleusa pri dozama do 2000 mg/kg na dan.
Apremilast was studied in healthy subjects at a maximum total daily dose of 100 mg (given as 50 mg BID) for 4.5 days without evidence of dose limiting toxicities.
Apremilast je ispitan u zdravih ispitanika pri maksimalnoj ukupnoj dnevnoj dozi od 100 mg (davanoj kao 50 mg dva puta dnevno (BID)) tijekom 4,5 dana bez znakova toksičnosti koja bi ograničila dozu.
Apremilast-treated patients demonstrated statistically significant improvement in physical function, as assessed by the disability index of the health assessment questionnaire (HAQ-DI) change from baseline, compared to placebo at Weeks 16 in PALACE 1, PALACE 2 and PALACE 3 and in the pooled studies.
U ispitivanjima PALACE 1, PALACE 2 i PALACE 3 te u objedinjenim ispitivanjima, u 16. tjednu bolesnici liječeni apremilastom pokazali su statistički značajno poboljšanje fizičkog funkcioniranja, procijenjeno kao promjena pokazatelja invalidnosti u Upitniku za procjenu zdravlja (HAQ-DI) u odnosu na početnu vrijednost, u usporedbi s onima koji su primali placebo.
Aprepitant (125 mg/80 mg) is a substrate, a moderate inhibitor, and an inducer of CYP3A4.
Aprepitant (125 mg/80 mg) je supstrat, umjereni inhibitor i induktor izoenzima CYP3A4.
Aprepitant (mild CYP3A4/5 inducer)
Aprepitant (slab induktor CYP3A4/5)
aprepitant (to treat nausea and vomiting)
aprepitant (za liječenje mučnine i povraćanja)
aprepitant (used to treat nausea); some gases (such as enflurane, halothane and isoflurane) used to give a general anaesthetic.
aprepitant (primjenjuje se za liječenje mučnine); neki plinovi (kao što su enfluran, halotan i izofluran) koji se primjenjuju kao opći anestetici.
Aprepitant does not seem to interact with the P-glycoprotein transporter, as suggested by the lack of interaction of aprepitant with digoxin.
Aprepitant ne ulazi u interakciju s transporterom P-glikoproteinom, na što ukazuje nedostatak interakcije aprepitanta s digoksinom.
Aprepitant regimen
Režim s aprepitantom
Aprepitant regimen (N= 521) †
Režim s aprepitantom
Aprepitant should be used with caution in these patients (see sections 4.4 and 5.2).
U tih bolesnika aprepitant treba primjenjivati uz oprez (vidjeti dio 4.4 i 5.2).
aprepitant – antiemetic (used to reduce vomiting)
aprepitant - antiemetik (primjenjuje se za smirenje povraćanja)
aprepitant, used to prevent and control nausea (feeling sick) and vomiting.
aprepitant, koristi se za prevenciju i kontrolu mučnine i povraćanja;
aprepitant, used to prevent nausea and vomiting by cancer treatment,
aprepitant, za sprječavanje mučnine i povraćanja kod liječenja raka,
Aprepitant: AUC: ↑ 5-fold
Aprepitant: AUC: ↑ 5 puta
Apridra contains metacresol
Apidra sadrži metakrezol
Aprovel 150 mg film-coated tablets are supplied in blister packs of 14, 28, 30, 56, 84, 90 or 98 film- coated tablets.
Aprovel 150 mg filmom obložene tablete dostupne su u blister pakiranjima s 14, 28, 30, 56, 84 i 98 filmom obloženih tableta.
Aprovel 150 mg film-coated tablets are white to off-white, biconvex, and oval-shaped with a heart debossed on one side and the number 2872 engraved on the other side.
Aprovel 150 mg filmom obložene tablete su bijele do gotovo bijele, bikonveksne i ovalne, s utisnutom oznakom srca na jednoj i brojem 2872 na drugoj strani.
Aprovel 150 mg film-coated tablets.
Aprovel 150 mg filmom obložene tablete
Aprovel 150 mg tablets are white to off-white, biconvex, and oval-shaped with a heart debossed on one side and the number 2772 engraved on the other side.
Aprovel 150 mg tablete su bijele do gotovo bijele, bikonveksne i ovalne, s utisnutom oznakom srca na jednoj i brojem 2772 na drugoj strani.
Aprovel 150 mg tablets irbesartan
Aprovel 150 mg tablete irbesartan
Aprovel 150 mg tablets.
Aprovel 150 mg tablete
Aprovel 300 mg film-coated tablets are supplied in blister packs of 14, 28, 30, 56, 84, 90 or 98 film- coated tablets.
Aprovel 300 mg filmom obložene tablete dostupne su u blister pakiranjima s 14, 28, 30, 56, 84 i 98 filmom obloženih tableta.
Aprovel 300 mg film-coated tablets are white to off-white, biconvex, and oval-shaped with a heart debossed on one side and the number 2873 engraved on the other side.
Aprovel 300 mg filmom obložene tablete su bijele do gotovo bijele, bikonveksne i ovalne, s utisnutom oznakom srca na jednoj i brojem 2873 na drugoj strani.
Aprovel 300 mg film-coated tablets.
Aprovel 300 mg filmom obložene tablete
Aprovel 300 mg tablets are white to off-white, biconvex, and oval-shaped with a heart debossed on one side and the number 2773 engraved on the other side.
Aprovel 300 mg tablete su bijele do gotovo bijele, bikonveksne i ovalne, s utisnutom oznakom srca na jednoj i brojem 2773 na drugoj strani.
Aprovel 300 mg tablets irbesartan
Aprovel 300 mg tablete irbesartan
Aprovel 300 mg tablets.
Aprovel 300 mg tablete
Aprovel 75 mg film-coated tablets are supplied in blister packs of 14, 28, 30, 56, 84, 90 or 98 film- coated tablets.
Aprovel 75 mg filmom obložene tablete dostupne su u blister pakiranjima s 14, 28, 30, 56, 84, 90 ili 98 filmom obloženih tableta.
Aprovel 75 mg film-coated tablets are white to off-white, biconvex, and oval-shaped with a heart debossed on one side and the number 2871 engraved on the other side.
Aprovel 75 mg filmom obložene tablete su bijele do gotovo bijele, bikonveksne i ovalne, s utisnutom oznakom srca na jednoj i brojem 2871 na drugoj strani.
Aprovel 75 mg film-coated tablets.
Aprovel 75 mg filmom obložene tablete
Aprovel 75 mg tablets are white to off-white, biconvex, and oval-shaped with a heart debossed on one side and the number 2771 engraved on the other side.
Aprovel 75 mg tablete su bijele do gotovo bijele, bikonveksne i ovalne, s utisnutom oznakom srca na jednoj i brojem 2771 na drugoj strani.
Aprovel 75 mg tablets irbesartan
Aprovel 75 mg tablete irbesartan
Aprovel 75 mg tablets.
Aprovel 75 mg tablete
Aprovel can be taken with or without food.
Aprovel se može uzeti s hranom ili bez nje.
Aprovel in combination with aliskiren- containing medicines (used to treat essential hypertension) must not be used in patients with diabetes, or moderate or severe kidney impairment.
U kombinaciji s lijekovima koji sadrže aliskiren (koristi se za liječenje esencijalne hipertenzije), Aprovel se ne smije koristiti u bolesnika s dijabetesom, ili umjerenim do ozbiljnim oštećenjem funkcije bubrega.
Aprovel is also used to treat kidney disease in adults with hypertension and type 2 diabetes.
Aprovel se također koristi za liječenje bolesti bubrega u odraslih s hipertenzijom i šećernom bolešću tipa 2.
Aprovel is used in adult patients
Aprovel se primjenjuje u odraslih bolesnika za
Aprovel with food and drink
Aprovel s hranom i pićem
Aptivus 100 mg/ml oral solution
Aptivus 100 mg/ml oralna otopina
Aptivus 250 mg soft capsules
Aptivus 250 mg meke kapsule
Aptivus 250 mg soft capsules tipranavir
Aptivus 250 mg meke kapsule tipranavir
Aptivus capsules are not interchangeable with the oral solution.
Aptivus kapsule nisu zamjenjive s oralnom otopinom.
Aptivus capsules contain ethanol, macrogolglycerol ricinoleate and sorbitol (E420)
Aptivus kapsule sadrže etanol, makrogolglicerolricinoleat i sorbitol (E420)
Aptivus contains 7 % ethanol (alcohol), i.e. up to 400 mg per daily dose, equivalent to 8 ml of beer, or less than 4 ml of wine.
Aptivus sadrži 7 % etanola (alkohola), tj. do 400 mg po dnevnoj dozi, što odgovara 8 ml piva ili manje od 4 ml vina.
Aptivus in combination with low dose ritonavir may cause changes in your child’s heart rhythm and the electrical activity of your child’s heart.
Aptivus u kombinaciji s niskom dozom ritonavira može izazvati promjene u ritmu srca i električnoj aktivnosti srca.
Aptivus may lead to a loss of effectiveness of some medicines including: methadone, meperidine (pethidine), used as morphine substitutes
Aptivus može dovesti do gubitka učinkovitosti nekih lijekova uključujući: metadon, meperidin (petidin), primjenjuju se kao zamjena za morfin
Aptivus oral solution contains vitamin E. Your child should not take any additional vitamin E supplements.
Aptivus oralna otopina sadrži vitamin E. Vaše dijete ne smije dodatno uzimati dodatke koji sadrže vitamin E.
Aptivus oral solution is a clear yellow liquid.
Aptivus oralna otopina je bistra žuta tekućina.
Aptivus oral solution is indicated for: children from 2 to 12 years of age
Aptivus oralna otopina je indicirana za: djecu u dobi od 2 do 12 godina
Aptivus oral solution is not interchangeable with the capsules.
Aptivus oralna otopina nije zamjenjiva s kapsulama.
Aptivus should be prescribed by physicians who are experienced in the treatment of HIV-1 infection.
Aptivus moraju propisivati liječnici s iskustvom u liječenju infekcije virusom HIV-1.
Aptivus should neither be used by children under 2 years of age nor by adolescents 12 years of age or older.
Aptivus se ne primjenjuje u djece mlađe od 2 godine niti u adolescenata u dobi od 12 i više godina.
Aptivus soft capsules are indicated for:
Aptivus meke kapsule su indicirane za:
Aptivus soft capsules are pink coloured, oblong soft gelatin capsules with a black print imprint of ‘TPV 250’.
Aptivus meke kapsule su ružičaste, duguljaste meke kapsule od želatine s crno otisnutom oznakom ‘TPV 250’.
Aptivus soft capsules co-administered with low dose ritonavir should be taken with food (see section 5.2).
Aptivus meke kapsule, uz istodobnu primjenu niske doze ritonavira, uzimaju se s hranom (vidjeti dio 5.2).
Aptivus soft capsules should not be used by children under 12 years of age.
Aptivus meke kapsule se ne primjenjuju u djece mlađe od 12 godina.
Aptivus treatment is therefore appropriate for you.
Stoga je liječenje Aptivusom odgovarajuće za Vas.
Aptivus treatment is therefore appropriate for your child.
Stoga je liječenje Aptivusom odgovarajuće za Vaše dijete.
Aptivus with ritonavir is
ritonavirom primjenjuje uz
Aptivus with ritonavir must not be used in patients with moderate or severe problems with their liver or who are taking any of the following medicines: rifampicin (used to treat tuberculosis);
Aptivus s ritonavirom ne smije se koristiti u bolesnika s umjerenim do ozbiljnim problemima s jetrom ili osobama koje uzimaju bilo koji od sljedećih lijekova: rifampicin (koristi se za liječenje tuberkuloze);
Aptivus with ritonavir should be discontinued once signs of worsening liver function occur in patients with pre-existing liver disease.
Primjena Aptivusa s ritonavirom se mora prekinuti kad se pojave znakovi pogoršanja jetrene funkcije u bolesnika s prethodno prisutnom bolešću jetre.
Aptivus, co-administered with low
lumefantrina s Aptivusom, s niskom
Aptivus, co-administered with low
nisku dozu ritonavira nije utvrđena.
Aptivus, co-administered with low dose ritonavir, is indicated for combination antiretroviral treatment of HIV-1 infection in highly pre-treated children from 2 to 12 years of age with virus resistant to multiple protease inhibitors.
Aptivus, uz istodobnu primjenu niske doze ritonavira, indicirana je u kombiniranom antiretrovirusnom liječenju infekcije virusom HIV-1 u djece od 2 do 12 godina starosti koja su prethodno liječena višestrukim antiretrovirusnim lijekovima, a u kojih je virus otporan na veći broj inhibitora proteaze.
Aptivus, co-administered with low dose ritonavir, should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery or other medical conditions, or who are receiving medicinal products known to increase the risk of bleeding such as antiplatelet agents and anticoagulants or who are taking supplemental vitamin E. Patients taking Aptivus oral solution should be advised not to take any supplemental vitamin E.
Aptivus s niskom dozom ritonavira treba se primjenjivati s oprezom u bolesnika u kojih postoji rizik pojačanog krvarenja zbog traume, kirurškog zahvata ili drugih medicinskih stanja, ili koji dobivaju lijekove za koje se zna da povećavaju rizik krvarenja, kao što su antitrombotici i antikoagulansi, ili koji uzimaju dodatak vitamina E. Stoga se bolesnicima koji uzimaju Aptivus oralnu otopinu savjetuje da ne uzimaju dodatak vitamina E.
aPTT [x-fold upper limit of normal]
aPTV [x puta od gornje granice normale]
APV29005 enrolled 30 patients aged 6 to 11 (the majority of whom were treated with fosamprenavir / ritonavir 18/3 mg/kg twice daily or the adult tablet regimen), and 40 patients aged 12 to 18 (the majority of whom were treated with the adult tablet regimen).
U APV29005 uključeno je 30 bolesnika u dobi od 6 do 11 godina (od kojih je većina liječena fosamprenavirom/ritonavirom u dozi od 18/3 mg/kg 2 puta dnevno ili prema režimu primjene tableta za odrasle) i 40 bolesnika u dobi od 12 do 18 godina (od kojih je većina liječena režimom primjene tableta za odrasle).
AQL improvement
AQL poboljšanje
aquinavir
akvinavir
aquinavir/ritonavir 1,000/100 mg twice
akvinavir/ritonavir 1000/100 mg dva